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Background: Complications of chronic anal fissure (CAF) treatments are prompting interest in lower-risk therapies.
This study was conducted to compare nitroglycerin (NTG) 0.4% ointment with placebo for pain associated with
CAF.
Methods: In this randomized, double-blind, placebo-controlled trial, patients with one CAF and moderate-to-severe
pain (≥50 mm on a 100 mm visual analog scale [VAS]) received 375 mg NTG 0.4% (1.5 mg active ingredient) or
375 mg placebo ointment applied anally every 12 hours for 21 days. The primary end point was change from
baseline VAS score in 24-hour pain averaged over days 14–18. Review of data from patients who withdrew early
was blinded to treatment. To control for the confounding effects of analgesics, all patients received 650 mg
acetaminophen for headache prophylaxis before each application.
Results: A total of 247 patients were enrolled (NTG, n = 123; placebo, n = 124). The prespecified baseline
observation carried forward (BOCF) analysis found no significant difference between groups; however, a last
observation carried forward (LOCF) analysis showed a significant advantage for NTG. A post hoc analysis (LOCF/
BOCF hybrid) demonstrated a significant adjusted mean difference of −7.0 mm in favor of NTG 0.4% (95% CI −13.6,
–0.4; P = .038). Headache was the most common adverse event in the NTG (69.9%) and placebo (47.6%) groups.
Conclusions: This was the first placebo-controlled study that also controlled for the confounding effects of
analgesics used to treat NTG-induced headache. In patients with moderate-to-severe CAF pain, NTG 0.4% ointment
effectively reduced CAF pain compared with placebo.
Trial registration: ClinicalTrials.gov, NCT00522041
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The first approved prescription product to treat chronic
anal fissure (CAF) pain in the United States is nitrogly-
cerin (NTG) 0.4% ointment (Rectiv®, ProStrakan, Inc.,
Bedminster NJ). Before introduction of this ointment,
patients were limited to obtaining topical NTG from
compounding pharmacies, risking nonstandard doses,
contamination, and unknown homogeneity and stability.* Correspondence: Scott43@bellsouth.net
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reproduction in any medium, provided the orData indicate that 46% of NTG ointments prepared by
compounding pharmacies for the treatment of CAF do
not meet US Pharmacopeia standards for potency and
content uniformity [1].
Placebo-controlled trials investigated regimens of
NTG 0.1%, 0.2%, and 0.4% ointment and determined
NTG 0.4% twice daily to be the optimal dose for greatest
analgesic effect compared with placebo in patients with
CAF, without a significant increase in adverse events
(AEs) over the other NTG concentrations [2]. However,
few studies to date have specifically investigated thed. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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pain associated with CAF. The current study further ex-
amines the effects of NTG 0.4% ointment for moderate-
to-severe pain associated with CAF. Dose strengths of
NTG below 0.2% were not investigated here as prior
controlled study evidence had indicated that 0.4% BID
provided efficacy with an acceptable safety profile.
Methods
Study design and objective
This was a randomized, double-blind, placebo-controlled,
multinational study to compare the effects of NTG 0.4%
and placebo on pain associated with CAF. Pain relief was
chosen as an end point because current data on the effects
of NTG on healing rate are inconclusive, so the primary
benefit to patients of using NTG is pain relief. The
planned treatment duration was 21 days, as earlier studies
with NTG had shown no increase in pain difference from
placebo after 21 days. Specific design elements of the
study were developed in discussion with the US Food and
Drug Administration (FDA), including the primary and
other end points, inclusion and exclusion criteria, vital
signs and other clinical measurements, and inclusion of a
standard oral analgesic regimen for both study arms to
avoid any confounding effect of medications taken for
headache.
The study conformed to the principles of the Inter-
national Conference on Harmonisation guideline: Good
Clinical Practice and the Declaration of Helsinki [3,4].
The study protocol, including changes, was reviewed
and approved by institutional review boards and inde-
pendent ethics committees, and all patients provided
voluntary written informed consent. The trial is regis-
tered at ClinicalTrials.gov, no. NCT00522041. All sites
were monitored, and all data were 100% verified against
sources.
Participants
Women and men aged 18 to 75 years were eligible to
participate if they had a single, chronic posterior midline
anal fissure accompanied by anal pain during the 6 weeks
prior to screening and a 24-hour average pain score
of ≥50 mm (on a 100-mm visual analog scale [VAS]) at
baseline and on 2 of the 4 days before randomization,
indicating moderate-to-severe pain. Evidence of at least
one of the following criteria for chronic fissure also was
required for study inclusion: sentinel skin tag, hypertro-
phied anal papillae, exposed internal anal sphincter, fi-
brotic fissure margins, or fibrotic anal sphincter. Patients
had to be willing to discontinue or avoid nonprescrip-
tion and prescription medicine (apart from conservative
care fiber supplements, adequate fluid, and sitz baths)
for the treatment of CAF for the duration of the study, in-
cluding nonsteroidal anti-inflammatory drugs, acetylsalicylicacid (aspirin; except at low doses for cardiovascular prophy-
laxis [162 mg/day or ≤325 mg on alternate days]), acet-
aminophen (paracetamol), and any other analgesic for the
treatment of headache or any other condition.
Patients were ineligible if they had more than one anal
fissure, fistula-in-ano or anal abscess, inflammatory
bowel disease, fibrotic anal stenosis, anal fissure second-
ary to an underlying condition, or a history of anal sur-
gery. Additional key exclusion criteria included a recent
history of migraine or chronic headaches; hypotension
or uncorrected hypovolemia; increased intracranial pres-
sure or inadequate cerebral circulation; use of nitrogly-
cerin or any other nitric oxide donors, potassium
channel blockers, calcium channel blockers, phospho-
diesterase type 5 inhibitors, or any medications that
could cause a drop in blood pressure when given in
combination with nitrates; and the presence of any
chronic pain requiring treatment with prohibited
medications.
Randomization and treatment
Eligible patients were randomized to receive NTG 0.4%
ointment or placebo via an interactive voice response
system using a randomization schedule prepared by an
independent statistician. The randomization schedule
was stratified by severity of pain as indicated by baseline
VAS score (moderate 50–69 mm; severe ≥70 mm) and
by gender. Gender was chosen as a stratification variable
in case there were gender differences in response to
NTG or placebo.
Patients in the NTG group applied NTG 375 mg 0.4%
ointment (containing 1.5 mg active ingredient) twice
daily. Patients in the placebo group applied placebo
375 mg ointment into the anal canal twice daily. The
dose was measured by the patients using a measuring
line, with the study medication being delivered from
tubes. Compliance with treatment was determined by
measuring the weight of the tubes. Placebo and NTG
tubes were identical and could not be identified as NTG
or placebo by either patient or physician. Placebo oint-
ment was vehicle only and, apart from the lack of active
ingredient, was identical to the NTG ointment. Thus,
excipients and appearance/feel of the placebo ointment
was the same as that of the active NTG. All patients
were instructed to take acetaminophen 650 mg 30 mi-
nutes before each application to ensure consistent
prophylaxis for headache (a known AE of NTG) and to
reduce any confounding effect on reported pain, as pre-
viously described.
Outcome measures
The primary end point was absolute change from base-
line in patient-reported 24-hour average CAF pain inten-
sity as measured using the 100-mm VAS over days 14 to
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able measurement of acute pain [5] and is a validated
tool to measure clinically important changes in pain se-
verity [6]. The pain score was averaged over days 14 to
18 to minimize the effect of a bowel movement on pain
scores on an individual day.
Secondary end points were as follows: time to improve-
ment in 24-hour average VAS (defined as a decrease of
10 mm and 50% from baseline); patients’ global assessment
of treatment at day 21 (last assessed visit day); percentage of
responders, defined as patients with a decrease in 24-hour
average pain intensity VAS score of ≥10 mm and ≥50% from
baseline for treatment days 14 to 18; and absolute change in
24-hour average VAS score at days 7, 14, and 21 (not
reported).
Five clinic visits were scheduled (screening and days 0
[randomization], 7, 14, and 21). Patient global assess-
ment of 24-hour average pain intensity (VAS score) was
obtained on day 0 and daily thereafter at bedtime until
the evening before the day 21 assessment. Patients com-
pleted their final VAS and assessment of therapy on day
21 at the clinic. Patients who withdrew early from the
study were asked to continue to record VAS scores until
day 21.
Safety assessments included physical examination findings,
vital signs (blood pressure and heart rate), orthostatic
hypotension assessment, laboratory tests (hematology,
serum chemistry, and urinalysis), 12-lead electrocardiograms
(ECGs), and AEs and serious AEs.
Patients were instructed to complete daily diary cards to
record time of administration of study medication (NTG
ointment and acetaminophen), VAS assessments, number of
sitz baths, and incidence and severity of headaches. For pain,
patients were asked to record their response to the question
“What has been your average pain today?”on a VAS at the
end of each day.
Statistical analysis
Primary end point
The intent-to-treat (ITT) population, comprising all ran-
domized patients who received at least one dose of study
drug, was the primary analysis population. The primary
efficacy end point (absolute change from baseline in 24-
hour average CAF pain intensity for days 14 to 18 of
treatment) was assessed using an analysis of covariance
(ANCOVA) model with treatment and gender as factors
and baseline VAS pain score as a covariate. To compare
treatment groups, all statistical tests were two-sided and
performed using a 5% significance level, leading to 95%
(two-sided) confidence intervals (CIs).
For the primary end point, different approaches were used
to handle missing VAS data. For patients who withdrew be-
fore day 18, a zero change from baseline VAS score was im-
puted (ie, baseline observation carried forward [BOCF]). Forpatients who did not withdraw before day 18, any individual
missing VAS scores on days 14 to 18 were calculated as the
average of available scores between days 14 and 18. If all
VAS scores were missing between days 14 and 18 but the
patient had not withdrawn from the study before day 18,
the last nonmissing value was carried forward (ie, last obser-
vation carried forward [LOCF]).
A sensitivity analysis was also planned to assess the ef-
fect of missing data if more than 5% of patients had
missing data. This analysis used the average of available
VAS scores for days 14 to 18 (if any were available) or
the last nonmissing score up to day 18. If patients re-
ceived any other treatment after day 14 (or if treatment
was unknown), calculations were based on either (1)
average VAS scores on days 14 to 18 prior to any other
treatment or (2) the last nonmissing score up to day 18
if no scores existed for days 14 through 18. If patients
received any treatment before day 14 (or treatment un-
known), the last nonmissing VAS score prior to any
treatment was used. This supportive LOCF analysis was
prespecified to show what effect patient withdrawals
may have had on the primary BOCF analysis. It was only
triggered in the event of a significant number of with-
drawals (5% of all cases), which was indeed the case. In
addition, a supportive analysis on absolute change from
baseline VAS score was performed on the ITT population
using a repeated measures ANCOVA. All post-baseline
VAS scores up to (but excluding) the assessment made at
the last visit day (this assessment was not made in the
evening so was not consistent with other VAS scores)
were included until day 23. This model assumed that
any missing data were missing at random and an
autoregressive first order variance–covariance structure
should be used.
Because of concerns about the BOCF approach being
too conservative and the LOCF approach being too gen-
erous in their management of missing data, a third ap-
proach was recommended during regulatory review. In
this LOCF/BOCF hybrid analysis, an independent Data
Review Committee (DRC) previously unaffiliated with
the current study analyzed blinded data (eg, pain scores,
AE reports, study drug treatment duration, post-study
treatments for anal fissure) from patients for evidence of
early withdrawal due to pain relief. When evidence of
early effective pain relief was found, actual recorded pain
VAS scores from days 14 through 18 were used when
available; when these scores were unavailable, scores
obtained before day 14 were used (LOCF). For patients
who withdrew without evidence of early pain relief, a
zero change was imputed (BOCF).
Secondary end points
Secondary end points of time to improvement and per-
centage of responders were analyzed for the ITT
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sequential hypothesis testing was stopped when results
failed to reject the null hypothesis of no difference in an
end point at the 5% significance level. Analyses were
performed in the following order: time to improvement
for a 50% decrease in 24-hour average pain intensity
(VAS); time to improvement for a 10-mm decrease in
24-hour average pain intensity (VAS); percentage of re-
sponders who had a 50% decrease in 24-hour average
pain intensity from baseline to primary end point; and
percentage of responders who had a 10-mm decrease in
24-hour average pain intensity (VAS) from baseline to
primary end point. Absolute change in 24-hour average
VAS at days 7, 14, and 21 was analyzed using the same
ANCOVA model as the initial primary efficacy analysis.
The log-rank test was used to compare time to improve-
ment between groups stratified by baseline VAS and
gender. Patients’ global assessment of therapy at day 21
was compared between treatment groups using logistic
regression with treatment and gender as factors and
baseline VAS pain as a covariate.Safety
All AEs were analyzed according to severity and rela-
tionship to NTG 0.4%, with headache summarized sep-
arately and together with other AEs. Severity was rated
by the investigator as mild (no limitation of usualFigure 1 Patient disposition. NTG, nitroglycerin; VAS, visual analog scale.activities), moderate (some limitation of usual activities),
or severe (inability to undertake usual activities).
Sample size
The required sample size was determined to be 246 (123
per treatment group) to detect a difference in VAS score
of 10 mm (equivalent to 20% for a patient with a base-
line VAS of 50 mm), assuming a 24 mm standard devi-
ation, with significance level of 5% and power 90% using
a 2-sided test.
Results
The study took place at 45 sites in the United States,
Argentina, Brazil, and Mexico between August 2007 and
July 2008. The ITT population comprised 247 patients
(NTG 0.4% n = 123; placebo n = 124). Patient disposition
is shown in Figure 1.
Participants
In the NTG and placebo groups, 106 of 123 (86.2%) and
113 of 124 (91.1%) patients, respectively, completed the
study. There were 35 (28.5%) patients in the NTG group
and 36 (28.8%) patients in the placebo group who had
protocol violations, most of which were related to the
timing of the administration of acetaminophen with re-
spect to the application of NTG ointment. Median com-
pliance with the application of ointment was 95% in
both groups. However, 21 (17.1%) patients in the NTG
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<80% compliance. Median compliance with acetamino-
phen treatment was greater than 97% in both groups.
Patient demographics and baseline characteristics are
shown in Table 1. The distribution of patients by age,
gender, and race was similar between groups. The most
common medical conditions reported for all 247 patients
were hypertension (67 [27.1%] patients), constipation (27
[23.1%]), and hemorrhoids (50 [20.2%]). Patients were
evenly distributed between groups with respect to base-
line pain VAS score; approximately half of patients in
each group had moderate baseline pain (VAS 50–




For the primary end point of absolute change from base-
line in 24-hour pain averaged over days 14 to 18, the ad-
justed mean (standard error [SE]) change from baseline
VAS was −40.4 (3.1) mm in the NTG group and −34.9
(3.0) mm in the placebo group. The mean (95% CI) dif-
ference between groups was −5.4 (−12.3, 1.4) mm in
favor of NTG, but this difference was not significant
(P = .118).
The sensitivity analysis was performed because >5% of
patients had missing primary end point data. This ana-
lysis showed a significant adjusted mean (95% CI)Table 1 Patient demographics and baseline characteristics in
Characteristic





Baseline VAS, n (%)
Moderate 50–69 mm
Severe ≥70 mm









NTG nitroglycerin, SD standard deviation, VAS visual analog scale.
*Fisher’s exact test used for all between-group comparisons except age, which wasdifference between groups in change from baseline in
24-hour average pain at days 14 to 18 in favor of NTG
(−13.8, –0.6; P = .033).
The results of the supportive analysis on absolute
change from baseline VAS score using a repeated mea-
sures ANCOVA model are shown in Figure 2. The ad-
justed mean change from baseline in VAS score was
greater for the NTG group than for the placebo group at
all time points. The mean (95% CI) treatment difference
for the average of days 14 to 18 was −8.1 (−13.8, –2.3)
mm in favor of NTG. The greatest adjusted mean differ-
ence between treatment groups occurred on day 15.
The results of the regulatory-specified analysis (LOCF/
BOCF hybrid) are presented in Table 2. The estimated
mean (95% CI) difference between treatment groups in
the adjusted change from baseline VAS score was −7.0
(−3.6, –0.4) mm, a significant difference in favor of NTG
(P = .038). Analysis by the DRC indicated that 9 of the
27 patients who withdrew were deemed to have done so
because of early effective pain relief; 6 were in the NTG
group and 3 were in the placebo group.
Secondary end points
In the NTG group, 89 (72.4%) of 123 patients achieved
a ≥50 decrease in VAS score compared with 80 of 124
(64.5%) patients in the placebo group. Mean time to
improvement was 10.7 and 13.2 days, respectively
(P = .071). The number of patients who had a ≥10 mmintent-to-treat population
NTG 0.4% Placebo P value
(2-sided)*(n = 123) (n = 124)
46.5 (12.6) 43.4 (13.2) .057
65 (52.8) 66 (53.2) 1
.640
99 (80.5) 96 (77.4)
21 (17.1) 16 (12.9)
.899
57 (46.3) 59 (47.2)
66 (53.7) 65 (52.0)
roup)
29 (23.6) 28 (22.6) .881
27 (22.0) 23 (18.5) .530
20 (16.3) 17 (13.7) .597
26 (21.1) 18 (14.5) .187
38 (30.9) 29 (23.4) .200
23 (18.7) 15 (12.1) .162
compared using t test.
Figure 2 Treatment difference in VAS pain at each time point: Adjusted Mean With 95% CI (ITT Population). Includes all post-baseline
VAS scores prior to withdrawal and up to (but excluding) the assessment made at the last visit day. Adjusted means and CIs were derived from a
repeated measures ANCOVA model with an auto-regressive first-order structure, with treatment, time, country, gender, and treatment × time as
factors and baseline VAS pain as a covariate. ANCOVA, analysis of covariance; ITT, intent-to-treat; NTG, nitroglycerin; VAS, visual analog scale.
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group and 106 (85.5%) in the placebo group. Mean time
to improvement was 6.1 and 7.2 days, respectively
(P = .287).
In the analysis of patients’ global assessment of treat-
ment at day 21, 95 (77.2%) patients in the NTG group
and 102 (82.3%) patients in the placebo group answered
that the benefit of their treatment outweighed any AE
they experienced; this difference was not significant
(P = .277). The difference between groups in the percent-
age of responders was also not statistically significant: 73
(59.3%) patients in the NTG group and 62 (50.0%) pa-




Mean (SD) 72.7 (14.5)
Median (range) 73.0 (13, 100)
Days 14–18
Mean (SD) 30.7 (26.6)
Median (range) 20.6 (0, 94)
Change from baseline
Mean (SD) −42.0 (26.5)
Median −45.2 (−91, 18)
Adjusted mean (SE) −43.7 (3.0)
95% CI
P value
BOCF baseline observation carried forward, CI confidence interval, LOCF last observa
standard error.baseline in 24-hour average pain intensity for days 14 to
18 (P = .131).
Safety
The mean (SD) number of doses of study treatment was
36.4 (10.8) in the NTG group and 38.9 (8.7) in the pla-
cebo group. The most common AEs in the safety popu-
lation, the severity of AEs, and the percentage of
patients who had AEs leading to study discontinuation
are shown in Table 3. A total of 96 (78.0%) of 123
patients in the NTG group and 67 (54.0%) of 124 pa-
tients in the placebo group experienced at least one AE
during the study. The most common AEs overall wereain response for days 14-18: LOCF/BOCF hybrid analysis
Placebo Difference







−36.7 (2.9) −7.0 (3.3)
−13.6, –0.4
.038
tion carried forward, NTG nitroglycerin, SD standard deviation, SE
Table 3 Most common (≥2%) treatment-emergent
adverse events by treatment group (safety population),
severity, and study discontinuation
TEAEs NTG 0.4% Placebo
n (%) (n = 123) (n = 124)
Number of patients with ≥1 AE 96 (78.0) 67 (54.0)
Mild 31 (25.2) 15 (12.1)
Moderate 41 (33.3) 38 (30.6)
Severe 24 (19.5) 14 (11.3)
Headaches 86 (69.9) 59 (47.6)
Dizziness 6 (4.9) 2 (1.6)
Diarrhea 4 (3.3) 4 (3.2)
Nausea 2 (1.6) 5 (4.0)
Sinusitis 3 (2.4) 1 (0.8)
AEs leading to study discontinuation 9 (7.3) 4 (3.2)
Headache 7 (5.7) 1 (0.8)
Palpitations 1 (0.8) 0
Celiac disease 0 1 (0.8)
Diarrhea 0 1 (0.8)
Skin fissures 1 (0.8) 0
Pain of skin 0 1 (0.8)
Abbreviation: AE Adverse event, TEAE Treatment-emergent adverse event.
Table 4 Summary of headache adverse events (safety
population)
Headaches NTG 0.4% Placebo
(n = 123) (n = 124)
Total number of occurrences 972 254
Mean (SD) duration, h 2.5 (3.5) 4.4 (6.4)
Patients with ≥1 headache, n (%) 86 (69.9) 59 (47.6)
Mild, n (%) 27 (22.0) 16 (12.9)
Moderate, n (%) 39 (31.7) 32 (25.8)
Severe, n (%) 20 (16.3) 11 (8.9)
Abbreviation: NTG Nitroglycerin, SD Standard deviation.
Berry et al. BMC Gastroenterology 2013, 13:106 Page 7 of 10
http://www.biomedcentral.com/1471-230X/13/106headache, dizziness, diarrhea, and nausea. The NTG
group had a higher incidence of headache, but there
were no other notable differences between groups. More
patients in the NTG group (5.7%) than in the placebo
group (0.8%) had an AE of headache that led to study
discontinuation.
Of the 96 patients who reported AEs in the NTG
group, 84 (68.3%) had AEs that were considered related
to the study treatment. Of the 67 patients who reported
AEs in the placebo group, 52 (41.9%) had AEs that were
considered related to study treatment.
Severe AEs occurred in 24 (19.5%) patients in the
NTG group and 14 (11.3%) in the placebo group. Three
patients reported serious AEs, which were considered
unrelated to study treatment: osteomyelitis (n = 1) and
anal sphincterotomy (n = 1) in the NTG group and iron
deficiency anemia (n = 1) in the placebo group. No
deaths occurred during the study.
The most common AE in both groups was headaches,
occurring in 86 (69.9%) of 123 patients in the NTG
group and 59 (47.6%) of 124 patients in the placebo
group. The severity and mean duration of headaches is
shown in Table 4. Most headaches were mild or moder-
ate in severity and decreased in frequency over time [7];
severe headaches were reported in 20 (16.3%) patients in
the NTG group and 11 (8.9%) in the placebo group. The
mean duration of headaches was 2.5 h in the NTG
group and 4.4 h in the placebo group. Headache was themain AE that led to discontinuation in the NTG group
(7 patients; Table 3). Dizziness, a possible symptom of
orthostatic hypotension, was the second most common
AE reported during the study. A trend toward decreased
supine systolic and diastolic blood pressure was ob-
served after application of NTG ointment; values
remained steady after application of placebo ointment.
Diastolic blood pressure was typically restored upon
standing. Mild compensatory tachycardia was also evi-
dent in the NTG group, which is a normal physiologic
compensation for decreased blood pressure. However,
changes in blood pressure and heart rate in the NTG
group at visit 1 were less evident at visit 2. No trends
were noted in changes from baseline in hematology,
serum chemistry, urinalysis, physical examination, or
ECG. Anal fissures had resolved in 61 (49.6%) of 123 pa-
tients in the NTG group and 52 (41.9%) of 124 patients
in the placebo group.
Hepatotoxicity markers, measured because of acet-
aminophen use in this study, were comparable between
groups and presented no safety concerns. Most patients
took at least one concomitant medication during the
study: 99 (80.5%) of 123 patients in the NTG group and
90 (72.6%) of 124 patients in the placebo group. The
most commonly reported medication was acetylsalicylic
acid, taken by 16 (13.0%) patients in the NTG group and
14 (11.3%) patients in the placebo group.
Discussion
In this patient population with moderate-to-severe CAF
pain, the primary end point of absolute change in pain
response was not significant between treatment groups
in the prespecified analysis (BOCF) performed on this
data set. However, a subsequent regulatory-requested
post hoc analysis (LOCF/BOCF) found a statistically sig-
nificant difference between treatment groups in favor of
NTG (P = .038). Moreover, the sensitivity analysis, which
included all reported changes in VAS scores for both
treatment groups, also found a significant difference in
efficacy between treatment groups in favor of NTG
(P = .033).
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prespecified analyses contributed to these results. Because
more than 10% of all patients did not complete the study,
the conservative BOCF method of imputing missing data
for these patients may have been overly conservative if pa-
tients had a reduction in CAF pain and decided not to
complete the study. This hypothesis is supported by the fact
that the LOCF analysis showed a significant difference be-
tween the study groups. The sensitivity analysis took a less
conservative approach and used the last available VAS
scores at the time of discontinuation. As more patients in
the NTG group discontinued early (13.8% vs 8.9% in the
placebo group), the more conservative primary analysis led
to a smaller, nonsignificant treatment difference than that
determined in the sensitivity analysis. In addition, subse-
quent review of the 27 patients who withdrew determined
that more patients in the NTG group who discontinued did
so because of early effective pain relief (6 of 16 [37.5%] vs 3
of 11 [27.3%], respectively). The hybrid LOCF/BOCF ap-
proach was used a regulatory-requested analysis that also
demonstrated a significant difference in the primary end
point in favor of NTG.
Both groups demonstrated mean reductions in pain on
VAS scores in the range of 30 to 40 mm and, in both
groups, pain scores improved over time. Previous re-
search supports a VAS score change in the range of 10
to 17 mm as clinically relevant in adults [6]. A placebo
effect in CAF pain reduction is well documented and re-
lates to any nonsurgical therapy [8-11]. However, time to
improvement (≥50 decrease) in VAS scores was shorter
in the NTG group compared with the placebo group,
suggesting that patients receiving NTG experienced pain
relief sooner than did patients in the placebo group.
Moreover, the repeated measures analysis demonstrated
that the adjusted mean change in VAS score from base-
line was greater for the NTG group than for the placebo
group at all time points.
Several prospective, randomized, controlled trials have
been compared the efficacy and safety of topical NTG
with other agents in the treatment of anal fissure, in-
cluding lignocaine [12], botulinum toxin [13,14], and dil-
tiazem [15]. Results varied across these studies, with
NTG showing superior efficacy in 2 of the 4 trials
[12,14]. However, the dosages of NTG used in these tri-
als were lower than that used in the current trial, varying
from 0.2% NTG applied twice daily [12,14,15] to 0.2%
NTG three times daily [13], compared with 0.4% NTG
twice daily in the current study.
The design of the current study (placebo-controlled,
confirmed run-in period to measure the degree of pain,
and confirmation of CAF) controlled for many of the
known confounding factors of pain studies in CAF.
However, it is possible that the prespecified and second-
ary efficacy end points in this study were confounded bythe benefit from placebo ointment, investigator advice
on diet and toileting, natural resolution of the anal
fissure, or the twice-daily acetaminophen taken by all
patients to minimize headache, which may not be repre-
sentative of standard conservative care in the general
population. However, it is likely that our measurements
in the placebo group reflected a placebo ointment effect,
rather than natural resolution of the fissure, as patients
had CAF and moderate-to-severe pain for several days
prior to randomization. This may be explained partially
by the lubricating effect of the ointment. Furthermore,
within the strict environment of this placebo-controlled
trial, the absolute magnitude of difference between the
NTG and placebo groups was low, but the magnitude of
pain reduction from baseline in the NTG group was well
within what is accepted as clinically meaningful. In
addition, the dose of acetaminophen used was unlikely
to have had a noticeable analgesic effect on moderate-
to-severe pain from CAF. This is the first placebo-
controlled study that has also controlled for the
confounding effect of analgesics taken to treat NTG-
induced headache.
Headache was the most common treatment-related
AE. While more headaches occurred in the NTG group,
they were of a shorter duration than those in the placebo
group but more frequently reported to be moderate or
severe. Although 69.9% of NTG patients reported head-
aches during the study, 77.2% of NTG patients stated
that the benefit of the treatment they received
outweighed any AEs. These data support previous re-
ports on the use of NTG ointment for CAF, in which
headaches were transient, also occurred in the placebo
group, and did not interfere with treatment [16]. The in-
cidence of headache in the placebo group (47.6%) may
have been associated with the requirement for patients
to complete a daily diary to record incidence and sever-
ity of headaches, potentially encouraging reporting of
headaches. Specifically, patients were asked in the daily
diary “Did you experience a headache today?” This ap-
proach may have inflated both the placebo and NTG
headache responses over and above what is normally
reported in other studies.
The protocol-specified use of acetaminophen to ensure
consistent prophylaxis for headache could potentially
have contributed to anal fissure pain relief (other NTG
studies have not controlled for analgesic use). To control
for the possible confounding factor of analgesic use, a
prespecified dose of prophylactic acetaminophen was
mandated in this study and all other analgesics
prohibited. It is not proposed that patients should rou-
tinely receive acetaminophen as part of NTG therapy.
It is important to note that there was no attempt in
the study protocol to confirm healing of the fissure or
decrease the dose of NTG for patients who experienced
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Conclusions
The common, painful condition of CAF would benefit
from a clinically acceptable, low-risk, moderately priced,
and reliably manufactured medication. The FDA recently
approved an NTG 0.4% ointment, which appears to pro-
vide effective relief of CAF pain, without risk of sphinc-
ter injury and with an acceptable safety profile, and to
offer a standardized formulation of an agent that had
previously been given to patients through an unregulated
pharmacy compounding process. In this randomized,
double-blind, placebo-controlled trial, the first placebo-
controlled trial that controlled for the confounding effect
of analgesics taken to treat NTG-induced headache,
NTG 0.4% effectively reduced moderate-to-severe CAF
pain compared with placebo. The duration of treatment
with NTG remains to be determined, but there is no
evidence that continuing treatment beyond the reso-
lution of pain symptoms is beneficial. In the longer
term, the analgesic effect of NTG may allow spontan-
eous healing of CAF, avoiding the need for surgical
intervention.
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